# Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

> **NCT05715606** · EARLY_PHASE1 · UNKNOWN · sponsor: **Anhui Provincial Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Metabolically Armed CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT05715606
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-10
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-05-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715606, "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05715606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*